📉 The Financial Deep Dive
Anthem Biosciences Limited has unveiled its financial results for the third quarter and nine months ended December 31, 2025, revealing a mixed performance. The company experienced a notable downturn in its quarterly revenue and profit figures, though its year-to-date performance offers a contrasting positive outlook.
The Numbers:
- Revenue Slump: Consolidated revenue for Q3 FY26 declined by 15.0% year-on-year (YoY) to ₹42.32 Cr (₹4,231.53 Mn) from ₹49.78 Cr in Q3 FY25. Sequentially, revenue dropped 23.1% from ₹55.00 Cr in Q2 FY26.
- PAT Decline: Consolidated Profit After Tax (PAT) fell sharply by 25.3% YoY to ₹9.28 Cr (₹928.17 Mn) compared to ₹12.43 Cr in the prior year. The sequential drop was even more pronounced, down 46.5% from ₹17.34 Cr in Q2 FY26.
- Positive 9M Trend: Despite the quarterly dip, the nine-month period ending December 31, 2025 (9M FY26) showed resilience. Consolidated PAT grew 9.0% YoY to ₹40.20 Cr from ₹36.86 Cr in 9M FY25.
- Margin Improvement: A silver lining was the improvement in EBITDA margins. Standalone Q3 FY26 EBITDA margin stood at a robust 48.45%, a significant jump from 38.01% in Q3 FY25. Consolidated EBITDA margin also improved YoY to 39.00% from 36.42%.
- Exceptional Item: The company recorded an exceptional item of ₹2.54 Cr on a consolidated basis (₹2.50 Cr standalone) representing a provision for upcoming new Labour Codes, impacting the quarterly profitability.
While the provided filing does not include a transcript of an analyst call, the significant sequential and year-on-year decline in quarterly revenue and PAT, coupled with an exceptional charge, presents key areas for investor scrutiny. The improvement in standalone EBITDA margins YoY warrants further investigation into cost efficiencies or product mix changes, especially in light of the revenue drop.
Red Flags:
The primary red flag is the consistent decline in revenue and PAT on both quarterly and sequential bases. While the 9M growth is positive, the Q3 performance suggests short-term operational or market headwinds are impacting the company. The provision for labour codes, though an exceptional item, further pressured the quarterly results.
So What?
For retail investors, Anthem Biosciences' Q3 results signal a period of quarterly contraction that warrants close monitoring. The divergence between the strong 9M PAT growth and the weak Q3 performance highlights the need to understand the sustainability of the company's revenue streams and cost management strategies. The recent listing on July 21, 2025, means the market is still assessing its fundamental strength, making these quarterly results critical. Investors should watch for management commentary on future demand, order pipeline, and the impact of the labour code provisions beyond this quarter.
---
🚩 Risks & Outlook
The immediate risk is the continuation of the revenue and PAT decline into Q4 FY26, which could signal a more systemic issue rather than a quarterly blip. The effective integration and cost management post-implementation of new labour codes will also be key. Investors should monitor order book developments and any further clarity on the drivers behind the sequential margin decline despite YoY improvements.
🚀 Strategic Analysis & Impact
This quarter's performance, particularly the revenue slide, raises questions about short-term demand or competitive pressures. However, the substantial YoY improvement in standalone EBITDA margins suggests effective operational control or a favourable product mix. The provision for labour codes, while impacting Q3, is a forward-looking adjustment for regulatory compliance, which is standard practice. The allotment of new shares via ESOP exercise, raising approximately ₹1.05 Cr, marginally increases the company's equity base without significant dilution. The unqualified auditor's reports provide confidence in the financial reporting.